Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Please share Science & Enterprise

Crispr Licensed for Eye Disease Gene Therapies

Retinal gene therapy

A developer of inherited eye disease therapies is acquiring rights to the gene editing technology Crispr for treatments that work inside the eyes. . . . → Read More: Crispr Licensed for Eye Disease Gene Therapies

Delivery Tech Licensed for CBD Epilepsy Nasal Spray

Blooming cannibis plant

A company is developing a nasal spray for epilepsy symptoms with a cannabis extract delivered in nanoscale polymer particles to the brain. . . . → Read More: Delivery Tech Licensed for CBD Epilepsy Nasal Spray

Biotechs Partner on Agitation Detection Technology

Sad, depressed

Two developers of treatments and tools for neurological diseases are developing a system for early detection of agitation, a symptom of psychiatric disorders. . . . → Read More: Biotechs Partner on Agitation Detection Technology

New Company Forms to Ease Scientific Data Operations

Data pointing finger

A new company spun off from Harvard University aims to simplify data analysis, management, and collaboration for life science researchers. . . . → Read More: New Company Forms to Ease Scientific Data Operations

Pharma Gains Synthetic DNA for Rare Diseases in $1B+ Deal

Brain activity graphic

A French biopharmaceutical company is gaining access to a technology using synthetic nucleic acids to treat rare genetic neurological diseases. . . . → Read More: Pharma Gains Synthetic DNA for Rare Diseases in $1B+ Deal

Pharma, Biotech Partner on Off-the-Shelf Cell Therapies

Mitochondria illustration

A biotechnology enterprise is teaming with a pharmaceutical company to develop off-the-shelf therapies for malfunctioning mitochondria, energy centers of cells. . . . → Read More: Pharma, Biotech Partner on Off-the-Shelf Cell Therapies

GSK, Biotech Partner on Neuro Antibodies in $2.2B Deal

Brain activity graphic

GlaxoSmithKline and biotechnology company Alector Inc. agreed to co-develop two synthetic antibodies for treating neurodegenerative disorders. . . . → Read More: GSK, Biotech Partner on Neuro Antibodies in $2.2B Deal

Microbiome Drug Candidate Licensed in $525M Deal

C. difficile in petri dish

A therapy designed to regenerate healthy gut microbes for treating dangerous intestinal infections is licensed for commercialization to Nestlé Health Science. . . . → Read More: Microbiome Drug Candidate Licensed in $525M Deal

Patent Awarded for Safer Cancer Drug Delivery

Chemotherapy vials

A pharmaceutical R&D company is receiving a patent for its process that encapsulates and better targets chemotherapy drugs for cancer patients. . . . → Read More: Patent Awarded for Safer Cancer Drug Delivery

Gene Therapy Company Starts-Up, Gains $200M

Adeno-associated virus

A new company is underway commercializing research on gene therapies for inherited diseases, staked to an initial investment of $200 million. . . . → Read More: Gene Therapy Company Starts-Up, Gains $200M